记者昨日从国家发展和改革委获悉，发改委已下发通知，决定从10月8日起调整部分抗肿瘤、免疫和血液系统类等药品的最高零售限价、共涉及95个品种、200多个代表剂型规格，平均降价幅度为17%。

Reporters yesterday from the national development and reform committee learned,Development and reform commission has issued a notice,A decision from October 8 up to regulate some antitumor/The immune and blood system drugs such as the highest retail price/Inoled a total of 95 varieties/More than 200 delegates dosage form specification,The average price cut of 17%.

　　国家发改委有关负责人指出，这次价格调整对日费用高的药品加大了降价力度，对日费用低的药品不降价，鼓励价格相对低廉药品的生产供应；对部分临床供应紧张的血液制品适当提高了价格，对专利等创新型药品适当控制降价幅度，利用价格杠杆促进药品的研发创新；对原单独定价药品，进一步缩小了与统一定价药品之间的价差，以促进市场公平竞争。(记者 孙春祥)

The national development and reform commission officials pointed out,The price adjustment, to the high cost of drugs increase the price cut strength,To low cost, the drug is not depreciate,Encourage price are relatively cheap drugs production supply;For some clinical supplies blood products appropriately raise the price,Such as patent innovative drug properly control the price range,Use the price lever to promote the pharmaceutical research and development innovation;The original single drug pricing,Further narrowed and unified pricing between drug price,In order to promote fair competition in the market.(Reporter SunChunXiang)